Literature DB >> 18855968

Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry.

Joanna Will1, Dirk A Wolters, William S Sheldrick.   

Abstract

Cisplatin binding sites in human serum proteins have been characterised by using combined multidimensional liquid chromatography and ESI tandem mass spectrometry (MudPIT). Following incubation periods of 3 h for cisplatin-blood serum mixtures and subsequent trypsin digestion, MS-MS spectra were recorded for individual peptides that had been separated by SCX and RP liquid chromatography. Matching of the MS-MS spectra to theoretical sequences that were generated for human proteins in the SWISS-PROT database led to the identification of specific binding sites in human serum albumin (HSA), serotransferrin (Trfe) and other abundant serum proteins (A2mg, A1at, Apoa1, Apoa2). The cisplatin coordination sites in HSA and Trfe were confirmed by independent MudPIT studies on cisplatin reaction mixtures with the individual proteins. A total of five specific binding sites were identified for HSA, including the cysteine residue C34, two methionine sites (M329, M548) and the tyrosine and aspartate O-donor sites Y150 (or Y148) and D375 (or E376). Methionine-256 was established as a cisplatin coordination site for Trfe in addition to the O-donor sites E265, Y314, E385 and T457. Inspection of the protein structures indicates that the preferred residues belong either to peripheral alpha helices or to flexible loops within the protein-binding pockets. O-donor residues dominate as cisplatin binding sites for other abundant serum proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855968     DOI: 10.1002/cmdc.200800151

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  6 in total

1.  Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.

Authors:  Francesca Magherini; Alessandra Modesti; Luca Bini; Michele Puglia; Ida Landini; Stefania Nobili; Enrico Mini; Maria Agostina Cinellu; Chiara Gabbiani; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2010-01-29       Impact factor: 3.358

2.  Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitin.

Authors:  Ting Zhao; Fred L King
Journal:  J Biol Inorg Chem       Date:  2011-03-02       Impact factor: 3.358

3.  Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2.

Authors:  Masaki Miyazawa; Alexander R Bogdan; Yoshiaki Tsuji
Journal:  Cell Chem Biol       Date:  2018-11-15       Impact factor: 8.116

4.  Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS.

Authors:  Michael Groessl; Mattia Terenghi; Angela Casini; Lisa Elviri; Ryszard Lobinski; Paul J Dyson
Journal:  J Anal At Spectrom       Date:  2010-03       Impact factor: 4.023

5.  Cross-linking of the DNA repair protein O6-alkylguanine DNA alkyltransferase to DNA in the presence of cisplatin.

Authors:  Xun Ming; Erin D Michaelson-Richie; Arnold S Groehler; Peter W Villalta; Colin Campbell; Natalia Y Tretyakova
Journal:  DNA Repair (Amst)       Date:  2020-03-19

Review 6.  The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry.

Authors:  Jingchen Wang; Jianmei Tao; Shuailong Jia; Meiqin Wang; Hongliang Jiang; Zhifeng Du
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.